BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND RB1, OSRC, ENSG00000139687, 5925, RB, P06400 AND Diagnosis
16 results:

  • 1. A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors.
    Němejcová K; Šafanda A; Bártů MK; Michálková R; Drozenová J; Fabian P; Hausnerová J; Laco J; Matěj R; Méhes G; Škapa P; Stružinská I; Dundr P
    Diagn Pathol; 2023 Feb; 18(1):32. PubMed ID: 36855066
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous ovarian Carcinoma.
    Manning-Geist B; Gordhandas S; Liu YL; Zhou Q; Iasonos A; Da Cruz Paula A; Mandelker D; Long Roche K; Zivanovic O; Maio A; Kemel Y; Chi DS; O'Cearbhaill RE; Aghajanian C; Weigelt B; Chui MH; Grisham RN
    Clin Cancer Res; 2022 Oct; 28(20):4456-4465. PubMed ID: 35443055
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Corded and Hyalinized Endometrioid Adenocarcinoma (CHEC) of the Uterine Corpus are Characterized by CTNNB1 Mutations and Can Show Adverse Clinical Outcomes.
    Ladwig NR; Umetsu SE; Zaloudek C; Rabban J; Garg K
    Int J Gynecol Pathol; 2021 Mar; 40(2):103-115. PubMed ID: 32909971
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts.
    McCool KW; Freeman ZT; Zhai Y; Wu R; Hu K; Liu CJ; Tomlins SA; Fearon ER; Magnuson B; Kuick R; Cho KR
    Cancer Res; 2020 Feb; 80(4):877-889. PubMed ID: 31806642
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Circulating miRNA Profiling in Plasma Samples of ovarian cancer Patients.
    Penyige A; Márton É; Soltész B; Szilágyi-Bónizs M; Póka R; Lukács J; Széles L; Nagy B
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540229
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Uptake of prenatal diagnostic testing for retinoblastoma compared to other hereditary cancer syndromes in the Netherlands.
    Dommering CJ; Henneman L; van der Hout AH; Jonker MA; Tops CM; van den Ouweland AM; van der Luijt RB; Mensenkamp AR; Hogervorst FB; Redeker EJ; de Die-Smulders CE; Moll AC; Meijers-Heijboer H
    Fam Cancer; 2017 Apr; 16(2):271-277. PubMed ID: 27826806
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Intraindividual genomic heterogeneity of high-grade serous carcinoma of the ovary and clinical utility of ascitic cancer cells for mutation profiling.
    Choi YJ; Rhee JK; Hur SY; Kim MS; Lee SH; Chung YJ; Kim TM; Lee SH
    J Pathol; 2017 Jan; 241(1):57-66. PubMed ID: 27741368
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas.
    Uehara Y; Oda K; Ikeda Y; Koso T; Tsuji S; Yamamoto S; Asada K; Sone K; Kurikawa R; Makii C; Hagiwara O; Tanikawa M; Maeda D; Hasegawa K; Nakagawa S; Wada-Hiraike O; Kawana K; Fukayama M; Fujiwara K; Yano T; Osuga Y; Fujii T; Aburatani H
    PLoS One; 2015; 10(6):e0128066. PubMed ID: 26043110
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer.
    Szabova L; Bupp S; Kamal M; Householder DB; Hernandez L; Schlomer JJ; Baran ML; Yi M; Stephens RM; Annunziata CM; Martin PL; Van Dyke TA; Weaver Ohler Z; Difilippantonio S
    PLoS One; 2014; 9(4):e95649. PubMed ID: 24748377
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer.
    Lange CA; Yee D
    Endocr Relat Cancer; 2011 Aug; 18(4):C19-24. PubMed ID: 21613412
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk.
    Knappskog S; Lønning PE
    Oncotarget; 2011 Mar; 2(3):251-8. PubMed ID: 21436469
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. [Gigantic ovarian and suprarenal cysts ten years after enucleation of unilateral retinoblastoma].
    Krstić V; Smoljanić Z; Djurović J; Marković V; Kosanović-Jaković N
    Srp Arh Celok Lek; 2008; 136(11-12):658-61. PubMed ID: 19177832
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Effects of common germ-line genetic variation in cell cycle genes on ovarian cancer survival.
    Song H; Hogdall E; Ramus SJ; Dicioccio RA; Hogdall C; Quaye L; McGuire V; Whittemore AS; Shah M; Greenberg D; Easton DF; Kjaer SK; Pharoah PD; Gayther SA
    Clin Cancer Res; 2008 Feb; 14(4):1090-5. PubMed ID: 18281541
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Declining trends of epithelial ovarian cancer in California.
    Morris CR; Rodriguez AO; Epstein J; Cress RD
    Gynecol Oncol; 2008 Jan; 108(1):207-13. PubMed ID: 18028989
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. [Genetic alterations in the genesis and development of ovarian cancer].
    Okamoto A; Yokoyama S; Terashima Y
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):1971-6. PubMed ID: 1358031
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. An analysis of abnormalities of the retinoblastoma gene in human ovarian and endometrial carcinoma.
    Sasano H; Comerford J; Silverberg SG; Garrett CT
    Cancer; 1990 Nov; 66(10):2150-4. PubMed ID: 2224770
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.